Direxion Daily TSLA Bull 1.5X Shares

ProShares UltraShort Bloomberg Natrl Gas

GraniteShares 1.5x Long NVDA Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Bank Of Montreal

GraniteShares 1.25x Long Tesla Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

ProShares UltraShort Silver

Direxion Daily FTSE China Bull 3X ETF

GraniteShares 1.5x Long Coinbase Daily ETF

ProShares Ultra Bloomberg Natural Gas

T-REX 2X Inverse Tesla Daily Target ETF

Volatility Shares Trust 2x Ether ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bull 3X ETF

United States Natural Gas

ProShares Ultra Silver

Direxion Daily Gold Miners Bull 3X ETF

iShares US Home Construction

Direxion Daily Small Cap Bull 3X ETF

Incannex Healthcare Limited American Depositary Shares

Innovative Eyewear Inc. Common Stock

Septerna Inc. Common Stock

HWH International Inc. Common Stock

DevvStream Corp. Common Stock

Rigetti Computing Inc. Common Stock

ZK International Group Co. Ltd Ordinary Share

Super Micro Computer Inc. Common Stock

CoreWeave Inc. Class A Common Stock

Oklo Inc.

Inno Holdings Inc. Common Stock

Gryphon Digital Mining Inc Common Stock

Next Technology Holding Inc. Ordinary Shares

Kindly MD Inc. Common Stock

Nuvve Holding Corp. Common Stock

Oriental Rise Holdings Limited Ordinary Shares

Classover Holdings Inc. Class B Common Stock

MicroAlgo Inc. Ordinary Shares

Hyperscale Data Inc. Common Stock

AgriFORCE  Growing Systems Ltd. Common Shares

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

Click here to get full coverage on UroGen Pharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

UroGen Pharma First Quarter 2025 Earnings: Misses Expectations  simplywall.st

UroGen Pharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

Click here to get full coverage on URGN: UroGen Pharma's Stock Maintains "Buy" Rating with $55 Targ - GuruFocus

URGN: UroGen Pharma's Stock Maintains "Buy" Rating with $55 Targ  GuruFocus

URGN: UroGen Pharma's Stock Maintains "Buy" Rating with $55 Targ - GuruFocus

Click here to get full coverage on UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Stock Titan

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update  Stock Titan

UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Stock Titan

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript - Insider Monkey

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript  Insider Monkey

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer  Business Wire

UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire

Click here to get full coverage on Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Nasdaq

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?  Nasdaq

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Nasdaq

Click here to get full coverage on UroGen Pharma (URGN) Awaits FDA Decision on UGN-102 - GuruFocus

UroGen Pharma (URGN) Awaits FDA Decision on UGN-102  GuruFocus

UroGen Pharma (URGN) Awaits FDA Decision on UGN-102 - GuruFocus

Click here to get full coverage on UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences  Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Stron - GuruFocus

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Stron  GuruFocus

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Stron - GuruFocus

Click here to get full coverage on Analyst Maintains Buy Rating for UroGen Pharma (URGN) | URGN Sto - GuruFocus

Analyst Maintains Buy Rating for UroGen Pharma (URGN) | URGN Sto  GuruFocus

Analyst Maintains Buy Rating for UroGen Pharma (URGN) | URGN Sto - GuruFocus

Click here to get full coverage on UroGen (URGN) Awaits FDA Decision on Promising Bladder Cancer Tr - GuruFocus

UroGen (URGN) Awaits FDA Decision on Promising Bladder Cancer Tr  GuruFocus

UroGen (URGN) Awaits FDA Decision on Promising Bladder Cancer Tr - GuruFocus

Click here to get full coverage on Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?  Yahoo Finance

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on UroGen Pharma (URGN) Maintains 'Buy' Rating with $25 Price Targe - GuruFocus

UroGen Pharma (URGN) Maintains 'Buy' Rating with $25 Price Targe  GuruFocus

UroGen Pharma (URGN) Maintains 'Buy' Rating with $25 Price Targe - GuruFocus

Click here to get full coverage on UroGen Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

UroGen Pharma Reports First Quarter 2025 Financial Results and P  GuruFocus

UroGen Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

Click here to get full coverage on $URGN stock is up 7% today. Here's what we see in our data. - Nasdaq

$URGN stock is up 7% today. Here's what we see in our data.  Nasdaq

$URGN stock is up 7% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Business Wire

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025  Business Wire

UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Business Wire

Click here to get full coverage on Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)  Yahoo Finance

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance

Click here to get full coverage on UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate - Stock Titan

UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate  Stock Titan

UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate - Stock Titan

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Click here to get full coverage on Urogen Pharma Ltd reports results for the quarter ended March 31 - Earnings Summary - TradingView

Urogen Pharma Ltd reports results for the quarter ended March 31 - Earnings Summary  TradingView

Urogen Pharma Ltd reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on (URGN) Long Term Investment Analysis - news.stocktradersdaily.com

(URGN) Long Term Investment Analysis  news.stocktradersdaily.com

(URGN) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - Stock Titan

UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy  Stock Titan

UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - Stock Titan

Click here to get full coverage on UroGen Pharma earnings missed by $0.13, revenue fell short of estimates - Investing.com

UroGen Pharma earnings missed by $0.13, revenue fell short of estimates  Investing.com

UroGen Pharma earnings missed by $0.13, revenue fell short of estimates - Investing.com

Click here to get full coverage on UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102  Business Wire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha

UroGen stock in focus after IconOVir deal (URGN:NASDAQ)  Seeking Alpha

UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Stock Titan

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC  Stock Titan

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Stock Titan

Click here to get full coverage on UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha

UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN)  Seeking Alpha

UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - simplywall.st

Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67%  simplywall.st

Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - simplywall.st

Click here to get full coverage on Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO - Nasdaq

Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO  Nasdaq

Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO - Nasdaq

Click here to get full coverage on UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy  Seeking Alpha

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha

Click here to get full coverage on OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Business Wire

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment  Business Wire

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Business Wire

Click here to get full coverage on UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Business Wire

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer  Business Wire

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Business Wire

Click here to get full coverage on New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Business Wire

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC  Business Wire

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Business Wire

Click here to get full coverage on UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC  Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire

Click here to get full coverage on UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates  Benzinga

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga

Click here to get full coverage on Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - MSN

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?  MSN

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - MSN

Click here to get full coverage on UroGen Pharma: There Is Some Potential Here (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: There Is Some Potential Here (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: There Is Some Potential Here (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen Announces FDA Advisory Committee for UGN-102, an Investig - GuruFocus

UroGen Announces FDA Advisory Committee for UGN-102, an Investig  GuruFocus

UroGen Announces FDA Advisory Committee for UGN-102, an Investig - GuruFocus

Click here to get full coverage on (URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

(URGN) Pivots Trading Plans and Risk Controls  news.stocktradersdaily.com

(URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer | URGN Stock News - GuruFocus

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer | URGN Stock News  GuruFocus

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer | URGN Stock News - GuruFocus

Click here to get full coverage on High Growth Tech Stocks In The US To Watch April 2025 - simplywall.st

High Growth Tech Stocks In The US To Watch April 2025  simplywall.st

High Growth Tech Stocks In The US To Watch April 2025 - simplywall.st

Click here to get full coverage on UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102  Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire

Click here to get full coverage on UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025  Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Business Wire

Click here to get full coverage on UroGen Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks

UroGen Pharma’s Earnings Call Highlights Progress and Challenges  TipRanks

UroGen Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks

Click here to get full coverage on 10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey

10 Best Small-Cap Growth Stocks to Buy Now  Insider Monkey

10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey

Click here to get full coverage on UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com

UroGen stock holds Buy rating, $64 target from H.C. Wainwright  Investing.com

UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com

Click here to get full coverage on UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024  Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire

Click here to get full coverage on UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025  Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire

Click here to get full coverage on This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday  Benzinga

This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Click here to get full coverage on UroGen Pharma Posts Wider Loss In Q4 - Quick Facts - Nasdaq

UroGen Pharma Posts Wider Loss In Q4 - Quick Facts  Nasdaq

URGN

Price Chart

Key Statistics

Technicals

About URGN

Latest News

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

URGN: UroGen Pharma's Stock Maintains "Buy" Rating with $55 Targ - GuruFocus

Advanced Charts

Top Gainers

Top Losers